D-penicillamine.
D-Pen represents an effective treatment for a proportion of patients with RA and PSS. Its status in the treatment of juvenile RA is uncertain. The best results will be obtained by a skillful, careful physician maintaining careful surveillance for toxicity. Neither the mode of action nor the mechanisms of toxicity are well understood in RA. Consequently, safer and more effective analogues of D-pen have not been produced.
Joyce
D A
DA
D001171:Arthritis, Juvenile / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D011307:Drug Prescriptions; D006801:Humans; D010396:Penicillamine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000188:drug therapy
D010396:Penicillamine